SMR3A

Across TCGA pan-cancer cohorts, SMR3A RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of SMR3A’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where SMR3A RNA is repressed in tumor relative to normal tissue. In most cancer types SMR3A is over-expressed in tumor, although a few such as THCA and HNSC show the opposite, repressed pattern.

THCA, HNSC, and UCEC are the cancer types where SMR3A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SMR3A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	All	−1.175	<.001	9	view →
HNSC	All	II,III,IV	−0.936	.005	4	view →
UCEC	All	All	+0.302	.032	2	view →
PRAD	All	All	−0.298	<.001	2	view →
LUSC	All	II,III,IV	−0.044	.027	2	view →
LIHC	All	All	+0.354	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

SMR3A–THCA

Open the THCA breakdown →